Pramiracetam is a synthetic racetam derivative for the purpose of cognitive enhancement, with preliminary evidence to support its usage in aiding long-term memory formation. Although the mechanisms are not well known at all, it might enhance acetylcholine synthesis.
Sources and Structure
Pramiracetam (full chemical name of Diisoprop-yl-(2-oxopyrrolidin-1-yl)acetamide and codename CI-879) is a synthetic racetam molecule with structural similarities to the parent molecule, Piracetam, and is used for nootropic purposes albeit in lower dosages. It appears to have been synthesized in 1984 on the basis of being a modification of piracetam that had more anti-amnesiac potential against electrocution.
Pramiracetam is a structural derivative from piracetam that was synthesized on the basis that is conferred more anti-amnesiac properties
Peak plasma concentrations (Cmax) following oral ingestion of pramiracetam in humans are 2.71+/-0.54µg/mL (400mg pramiracetam), 5.40+/-1.34µg/mL (800mg), 6.13+/-0.71µg/mL (1,200mg), and 8.98+/-0.71µg/mL (1,600mg) and elsewhere 600mg has recorded a peak value at 5.80-6.80µg/mL.
The half-life has been noted to be 2.3-3.9 hours in dogs although a human study using a dosage range of 400-1,600mg pramiracetam noted a more prolonged half-life at 4.5-6.5 hours whereas a previous one noted a much more variable half-life of 2-8 hours following 600mg pramiracetam.
Pramiracetam appears to be absorbed in humans and follows linear kinetics in the blood, it has a fairly prolonged yet variable half-life
The influence of pramiracetam (0.15-1.5mM) on hippocampal excitatory postsynaptic potentials induced by noted a change of -2.9+/-3.8% from baseline that failed to be significant. Similar to the inefficacy found above, pramiracetam has elsewhere failed to have affinity for dopaminergic, adrenergic, serotoninergic, GABAergic, muscarinic, and adenosinic receptors at an IC50 below 10μM.
No significant per se effects noted on hippocampal cells in vitro
Similar to Piracetam, the memory consolidating effects of pramiracetam can be abolished with an adrenalectomy, suggesting a vital role of the adrenal glands. Further studies have noted that aminoglutethimide (prevents conversion of cholesterol to pregnenolone) and epoxymexrenone (aldosterone receptor antagonist) can abolish the effects observed. Elevated corticosteroid levels in general have also been noted to block the effects of these racetam drugs.
Steroid metabolism, namely the aldosterone receptors, appears to be involved in the cognitive enhancing effects of pramiracetam
Pramiracetam has been noted to restore the alterations in EEG function of aged rats to a manner seen in youthful rats noted in the 5-20mg/kg range with efficacy exceeding 200-400mg/kg piracetam. Alterations in brain wave function have been noted in otherwise healthy rats given pramiracetam, and the magnitude of changes in corticol slow waves and hippocampal theta waves correlated with cognitive enhancement in a water maze test.
Pramiracetam appears to influence EEG readings, and this occurs per se in both elderly and young rats. The mechanisms underlying these alterations are not yet known
An intraperitoneal injection of pramiracetam (44-88mg/kg) to rats is able to increase high affinity choline uptake (HACU) in rat hippocampal slices within 30 minutes. This was not seen with piracetam or aniracetam, and both smaller (8.8mg/kg) and larger (176mg/kg) doses were ineffective. Elsewhere, pramiracetam (as well as piracetam) has been noted to normalize the changes induced by scopolamine on choline transport.
When tested in vitro, direct application of pramiracetam to hippocampal slices of naive animals failed to increase HACU.
Pramiracetam may be able to increase high-affinity choline uptake (HACU), the rate-limiting step of acetylcholine synthesis (see the coluracetam page for more information on HACU)
Memory and Cognition
The earliest study on the anti-amnesiac potential of pramiracetam reported that the amnesia-reversal potential of pramiracetam with peak efficacy (96% reversal) at 5mg/kg (effective in the range of 12.5-80mg/kg, intraperitoneal injection). This study noted a potency greater than piracetam, which was the basis of synthesizing pramiracetam. Elsewhere, amnesia from the anticholinergic toxin hemicholinium-3 is suppressed with preadministration of pramiracetam.
In regards to amnesiac studies in animals, it has limited evidence but appears to be more potent than piracetam
Exploratory activity appears to be differentially affected by pramiracetam, being increased at 15mg/kg and suppressed at 60mg/kg (30mg/kg had no effect).
In a study assessing the effects of kynurenic acid (glycine-binding site NMDA agonist) using pramiracetam as a comparator, 30mg/kg pramiracetam was able to enhance object recognition memory. Improvements in object recognition have been noted elsewhere with 30mg/kg pramiracetam (more effective than both 15mg/kg and 60mg/kg) to be comparable to 400mg/kg Piracetam. Step-down avoidance has also noted improvement with oral pramiracetam (100mg/kg) in mice taken 1-2 hours prior to the trial, with comparable efficacy to oxiracetam (same dose) but outperforming piracetam and either performing equally to or outperforming aniracetam. Performance in a water maze has been noted to also be improved after a single trial, with 10mg/kg being more effective than lower and higher doses.
Administration (intraperitoneal injections) of pramiracetam at 7.5-15mg/kg to rats over seven weeks of training in a 16-arm radial maze task was able to improve reference (long term) memory without an apparent effect on working memory. While 15mg/kg trended to be more effective than 7.5mg/kg, the difference did not appear to be significant.
Has been confirmed to facilitate long-term memory formation, although no apparent effect on working memory persists. There is efficacy in research animals following acute usage of pramiracetam prior to cognitive testing
In otherwise healthy elderly persons with memory loss, supplementation or pramiracetam over 12 weeks has been noted to improve objective memory retention to a larger degree than memory training (90 minutes weekly with tutors) although the two were additive. Otherwise healthy youth with cerebral injuries paired with memory complaints at a similar dose of pramiracetam (as sulphate; 400mg thrice daily) has noted improvements in memory and cognition, which persisted over 18 months of open label therapy and one month cessation.
In otherwise healthy volunteers given scopolamine after 10 days of pramiracetam supplementation (600mg twice daily) was able to partially reverse the amnesiac effects of scopolamine on episodic memory and selective attention tests.
Although the evidence is fairly limited and in either older subjects or youth with brain injuries, pramiracetam does appear to have nootropic potential after oral ingestion of the standard supplemental dosages in humans
Alzheimer& #039;s Disease
One pilot study using pramiracetam in persons with Alzheimer's disease (particular dose chosen based on what the subject responded to best, in the range of 1,200-4,000mg daily) failed to find any evidence of efficacy and suggested that pramiracetam may not be therapeutic.
Currently no evidence to support the usage of pramiracetam in reducing symptoms or pathology of Alzheimer's disease
The ability of pramiracetam to increase nitric oxide synthase (NOS) activity in the cortex of rats, which occurs at 300mg/kg intraperitoneal injections (to 20% higher than baseline) but not 100mg/kg seems to be potentiated with pretreatment with lithium as 100mg/kg pramiracetam can increase NOS to 40% of baseline in this instance.